INS and autoimmune disease: Most clinical trials of ICIs exclude patients with concomitant autoimmune diseases to avoid exacerbation of preexisting autoimmune diseases or increased risk of irAEs after ICI administration.[17] Researchers believe that the incidence of irAEs is higher in patients with a history of autoimmune disease or positive auto insulin antibodies prior to receiving ICIs.